The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report.
To describe the use of botulinum toxin type A (BTX-A) in radiation fibrosis syndrome (RFS). Retrospective case series. A large tertiary care cancer center. Twenty-three consecutive patients treated for sequelae of RFS with BTX-A. Not applicable. A description of the components of RFS thought to benefit from BTX-A injections and the patient's self-report of benefit from those injections. The sequelae of RFS for which BTX-A injection was thought to be indicated include radiation-induced cervical dystonia in 18 (78%), trigeminal nerve or cervical plexus neuralgia in 10 (43%), trismus in 7 (30%), migraine in 3 (13%), and thoracic pain in 1 (4%) patient. Most (87%) patients self-reported benefit from the injections. Initial clinical experience with the use of BTX-A as adjunctive treatment for select neuromuscular and musculoskeletal complications of RFS in a variety of cancer patients has been encouraging. Well-designed prospective studies are needed to clarify the potential beneficial role of BTX-A in specific sequelae of RFS.